OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation
Chen‐Song Huang, Ying‐Qin Zhu, Qiong‐Cong Xu, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 6
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

The role of m6A methylation in therapy resistance in cancer
Hengzhao Zhuang, Bo Yu, Dan Tao, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 88

N6-methyladenosine reader YTHDF family in biological processes: Structures, roles, and mechanisms
Lin Chen, Yang Gao, Simiao Xu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 50

Cisplatin in Liver Cancer Therapy
Sae Hamaya, Kyoko Oura, Asahiro Morishita, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10858-10858
Open Access | Times Cited: 43

Biological and pharmacological roles of m6A modifications in cancer drug resistance
Zaoqu Liu, Haijiao Zou, Qin Dang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 57

The emerging importance role of m6A modification in liver disease
Sheng Wang, Songsen Gao, Wufei Ye, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114669-114669
Open Access | Times Cited: 30

Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication
Huisheng Liu, Xue Qiao, Fan Yang, et al.
Autophagy (2024) Vol. 20, Iss. 7, pp. 1597-1615
Open Access | Times Cited: 9

ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression
Xueying An, Wenshu Wu, Lin Yang, et al.
Translational research (2023) Vol. 259, pp. 62-71
Closed Access | Times Cited: 20

ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A‐to‐I editing manner
Qi Liu, Chen‐Song Huang, Siyun Chen, et al.
Cell Proliferation (2024) Vol. 57, Iss. 10
Open Access | Times Cited: 5

M6AREG: m6A-centered regulation of disease development and drug response
Shuiping Liu, Lu Chen, Yintao Zhang, et al.
Nucleic Acids Research (2022) Vol. 51, Iss. D1, pp. D1333-D1344
Open Access | Times Cited: 22

Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy
Angel Guan, Justin Wong
Cancer Medicine (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 4

The biological function of the N6-Methyladenosine reader YTHDC2 and its role in diseases
Xudong Wu, Hui Chen, Kai Li, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4

The YTH domain‐containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets
Fenghe Li, Chong Zeng, Jie Liu, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 8
Open Access | Times Cited: 4

Emerging importance of m6A modification in liver cancer and its potential therapeutic role
Tao Chen, Wufei Ye, Songsen Gao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189299-189299
Closed Access

Decoding m6A mRNA methylation by reader proteins in liver diseases
Lijiao Sun, Xin Chen, Sai Zhu, et al.
Genes & Diseases (2023) Vol. 11, Iss. 2, pp. 711-726
Open Access | Times Cited: 10

Changes in m6A in Steatotic Liver Disease
Belinda J. Petri, Matthew C. Cave, Carolyn M. Klinge
Genes (2023) Vol. 14, Iss. 8, pp. 1653-1653
Open Access | Times Cited: 10

YTHDF2-regulated matrilin-3 mitigates post-reperfusion hemorrhagic transformation in ischemic stroke via the PI3K/AKT pathway
Hanze Chen, Guo Siping, Runnan Li, et al.
Journal of Neuropathology & Experimental Neurology (2024) Vol. 83, Iss. 3, pp. 194-204
Open Access | Times Cited: 3

Knockdown of YTHDF2 initiates ERS-induced apoptosis and cancer stemness suppression by sustaining GLI2 stability in cervical cancer
Fujian Wan, Fengwu Qiu, Yang Deng, et al.
Translational Oncology (2024) Vol. 46, pp. 101994-101994
Open Access | Times Cited: 3

Smooth Muscle Ythdf2 Abrogation Ameliorates Pulmonary Vascular Remodeling by Regulating Myadm Transcript Stability
Jie Wang, Yueyao Shen, Yuhui Zhang, et al.
Hypertension (2024) Vol. 81, Iss. 8, pp. 1785-1798
Closed Access | Times Cited: 3

YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A‐dependent DAPK3 degradation
Xuesong Bai, Jiemin Chen, Wen-Qin Zhang, et al.
Cancer Science (2023) Vol. 114, Iss. 11, pp. 4299-4313
Open Access | Times Cited: 8

RNA epigenetic modifications in digestive tract cancers: Friends or foes
Zekai Nian, Ming Deng, Lele Ye, et al.
Pharmacological Research (2024) Vol. 206, pp. 107280-107280
Open Access | Times Cited: 3

KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer
Litong Yao, Qian Hao, Mozhi Wang, et al.
Oncogene (2023) Vol. 42, Iss. 47, pp. 3514-3528
Open Access | Times Cited: 6

Page 1 - Next Page

Scroll to top